Ortho Clinical Diagnostics
{{Short description|Pharmaceutical company}}
{{Infobox company
| name = Ortho Clinical Diagnostics Holdings plc
| logo = Ortho Clinical Diagnostics logo.svg
| type = Public
| founded = {{Start date and age|1939}}
Linden, New Jersey, U.S.
| hq_location = 1001 US-202
| hq_location_city = Raritan, New Jersey
| hq_location_country = U.S.
| area_served = Worldwide
| key_people = {{ubl|Robert Yates (chairman)| Chris Smith (chief executive officer)|Joseph M. Busky (CFO)|Michael Schlesinger (CLO)}}{{cite web|title=Ortho Clinical Diagnostics Leadership|url=https://www.orthoclinicaldiagnostics.com/en-us/home/about-us|access-date=6 July 2016}}
| industry = Medical diagnostics
| owner = Quidel Corporation
| num_employees = 4,400 (2019)
| homepage = {{URL|http://www.orthoclinicaldiagnostics.com/|orthoclinicaldiagnostics.com}}
}}
Ortho Clinical Diagnostics (now QuidelOrtho) is an in vitro diagnostics company that made products and diagnostic equipment for blood testing. Ortho served two primary industries in the medical field: clinical laboratories, by producing platforms and assays that test for a variety of diseases, conditions, and substances; and immunohematology, by providing the means to ensure blood transfusion recipients receive appropriate and compatible blood.{{cite web|title=Who We Are|url=http://orthoclinical.com/en-us/about-us/who-we-are|website=Ortho Clinical Diagnostics|access-date=6 July 2016}}
Johnson and Johnson acquired Eastman Kodak's Clinical Diagnostics Division in 1994 (to form Johnson & Johnson Clinical Diagnostics), which was then merged with Ortho Diagnostic Systems in 1997. QuidelOrtho's global corporate offices are in Raritan, New Jersey, while their global research and development center is in Rochester, New York.
In 2014, The Carlyle Group purchased the company from Johnson & Johnson for $4.15 billion. Ortho Clinical Diagnostics now operated as an independent company,{{cite news|last=Daneman|first=Matthew|title=Carlyle to buy Ortho-Clinical for $4.15 billion|url=http://www.democratandchronicle.com/story/money/business/2014/01/16/carlyle-to-buy-ortho-clinical-for-415-billion/4509503/|access-date=23 March 2014|newspaper=Democrat and Chronicle|date=16 January 2014}}{{Cite web | url=https://www.carlyle.com/news-room/news-release-archive/carlyle-group-completes-acquisition-ortho-clinical-diagnostics-inc-oc | title=News & Media | Carlyle }}{{Cite web | url=http://www.businesswire.com/news/home/20150427006258/en/Ortho-Clinical-Diagnostics-Appoints-Industry-Veterans-Board | title=Ortho Clinical Diagnostics Appoints Industry Veterans to Board of Directors | date=27 April 2015 }} up until its acquisition by Quidel Corporation for $6 billion, on May 27, 2022.
History
1939: Ortho Products, Inc., is formed in Linden, New Jersey, as a division of Johnson & Johnson.
1944: Philip Levine, in the field of hematology, joins Ortho Products to continue his research into the mechanics of the Rh system in human blood.{{Cite news | url=https://www.nytimes.com/1987/10/20/obituaries/dr-philip-levine-87-is-dead-discovered-blood-s-rh-factor.html | title=Dr. Philip Levine, 87, is Dead; Discovered Blood's Rh Factor | newspaper=The New York Times | date=20 October 1987 | last1=Flint | first1=Peter B. }}
1997: Ortho Diagnostics Systems and Johnson & Johnson Clinical Diagnostics merge and begin operating as Ortho Clinical Diagnostics.{{Citation needed|date=July 2022}}
2001: Ortho becomes the first diagnostic company to receive US FDA approval for automated random access hepatitis tests.{{cite web |url=https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm088991.htm |title=Vitros Immunodiagnostic Products HBsAg Reagent Pack and Calibrator, and HBsAg Confirmatory Kit - P000044 |website=www.fda.gov |url-status=dead |archive-url=https://web.archive.org/web/20090709234039/http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm088991.htm |archive-date=2009-07-09}}{{Cite web | url=http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=13728 | title=Pharma commercial intelligence, news & analysis | Evaluate }}
2006: Ortho launches the first FDA-licensed test to screen blood donations for exposure to Chagas disease.{{Cite web|url=https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5607a2.htm|title=Blood Donor Screening for Chagas Disease --- United States, 2006--2007}}
2014: The Carlyle Group acquires Ortho Clinical Diagnostics for $4.15 billion.{{Cite web|url=https://dealbook.nytimes.com/2014/01/16/carlyle-buys-johnson-johnson-testing-division-for-4-15-billion/?_r=0|title=Carlyle Buys Johnson & Johnson Testing Division for $4.15 Billion|date=16 January 2014 }}
2015: Ortho receives FDA clearance for its ORTHO VISION Analyzer, which automates the full range of immunohematology testing and helps improve the safety of blood transfusions by reducing laboratories' reliance on manual methods.{{cite news|title=First Hospital Installs Ortho Vision Analyzer|url=http://www.news-medical.net/news/20151113/First-hospital-installs-Ortho-Vision-Analyzer.aspx|access-date=6 July 2016|work=News-Medical.net|date=13 Nov 2015}}{{cite news|last1=Lawrence|first1=Stacy|title=Ortho After the Carlyle Takeover: A Q&A with CEO Martin Madaus|url=http://www.fiercebiotech.com/medical-devices/ortho-after-carlyle-takeover-a-q-a-ceo-martin-madaus|access-date=6 July 2016|work=Fierce Biotech|date=25 Apr 2016}}
2017: FDA approves Ortho's HIV Combo test for the Vitros immunodiagnostic system. The test detects both HIV-1 and HIV-2 antibodies and the p24 antigen, and enables detection of HIV-1 acute infection earlier than previous assays.{{cite web|last1=360Dx Staff|title=Ortho Clinical Diagnostics Gets FDA Clearance for HIV Combo Test on Immunodiagnostic System|url=https://www.360dx.com/regulatory-news/ortho-clinical-diagnostics-gets-fda-clearance-hiv-combo-test-immunodiagnostic-system|website=360Dx.com|date=18 December 2017|access-date=19 December 2017}}
2021: Quidel announced it would acquire Ortho Clinical Diagnostics Holdings for $6 billion in cash and stock, increasing the range of COVID-19 antigen and antibody tests the business is able to offer. {{cite news| url = https://www.reuters.com/markets/deals/quidel-buy-ortho-clinical-diagnostics-6-billion-2021-12-23/| title = Quidel to buy Ortho Clinical for $6 bln to boost diagnostics portfolio| newspaper = Reuters| date = 12 February 2024}}
Business operations
Ortho produces in-vitro diagnostics equipment and associated assays and reagents, serving the clinical laboratories and immunohematology sectors of the medical field.{{cite news|last1=Porter|first1=Kiel|title=Carlyle Is Said to Hire Banks for Ortho Clinical Diagnostics IPO|url=https://www.bloomberg.com/news/articles/2017-12-06/carlyle-is-said-to-hire-banks-for-ortho-clinical-diagnostics-ipo|access-date=19 December 2017|work=Bloomberg News|publisher=Bloomberg LP|date=6 December 2017}}
Ortho sells its products in more than 125 countries and is targeting emerging markets for future growth.
References
{{Reflist}}